RMC-6236 is the furthest along in development of the KRAS inhibitors by Revolution Medicine. ThenGDA has a provision where trials can be shortened when the clinical evidence is overwhelmingly supports the efficacy of a drug. There is also a provision in trials with a control and test arm and the participants in the test arm are receiving overwhelming benefit, those in the control arm will get moved over to receiving the drug as it would be unethical to deprive them of its benefit.